Cargando…

Loss of MAGEC3 Expression Is Associated with Prognosis in Advanced Ovarian Cancers

SIMPLE SUMMARY: Familial studies connect variants in the X-linked gene MAGEC3 to early-onset ovarian cancers. In this retrospective cohort study, we determined that, unlike other MAGE family members, the MAGEC3 protein is normally expressed in ovarian tissue but is lost in half of the ovarian cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ellegate, James, Mastri, Michalis, Isenhart, Emily, Krolewski, John J., Chatta, Gurkamal, Kauffman, Eric, Moffitt, Melissa, Eng, Kevin H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833712/ https://www.ncbi.nlm.nih.gov/pubmed/35158998 http://dx.doi.org/10.3390/cancers14030731

Ejemplares similares

Combined BRCA2 and MAGEC3 Expression Predict Outcome in Advanced Ovarian Cancers
por: Omole, Emmanuel B., et al.
Publicado: (2022)

Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance
por: Dolan, Melissa, et al.
Publicado: (2019)

Establishment of MAGEC2‐knockout cells and functional investigation of MAGEC2 in tumor cells
por: Wang, Jingjing, et al.
Publicado: (2016)

MAGEC2 Correlates With Unfavorable Prognosis And Promotes Tumor Development In HCC Via Epithelial-Mesenchymal Transition
por: Gu, Xuefeng, et al.
Publicado: (2019)

The Performance of MAGEC X Spine Rods: A Comparative Retrieval Study
por: Tognini, Martina, et al.
Publicado: (2022)

MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis
por: Yang, Fan, et al.
Publicado: (2014)

The impact and surgeon perceptions of the suspension of the CE certification of MAGEC devices on clinical practice
por: Hothi, Harry
Publicado: (2022)

Sublaminar Band Fixation Provides Excellent Anchors for MAGEC Rod Distraction Systems
por: Rosenfeld, Samuel R., et al.
Publicado: (2023)

The MAGEC System for Spinal Lengthening in Children with Scoliosis: A NICE Medical Technology Guidance
por: Jenks, Michelle, et al.
Publicado: (2014)

Device-Related Complications Associated with Magec Rod Usage for Distraction-Based Correction of Scoliosis
por: Agarwal, Aakash, et al.
Publicado: (2019)

Role of tumor microenvironment in the efficacy of BCG therapy
por: Ibrahim, Omar M, et al.
Publicado: (2020)

Post-transcriptional regulation of cancer/testis antigen MAGEC2 expression by TRIM28 in tumor cells
por: Song, Xiao, et al.
Publicado: (2018)

Identification of MAGEC2/CT10 as a High Calcium-Inducible Gene in Triple-Negative Breast Cancer
por: Beasley, Heather K., et al.
Publicado: (2022)

NFκB-Activated COX2/PGE(2)/EP4 Axis Controls the Magnitude and Selectivity of BCG-Induced Inflammation in Human Bladder Cancer Tissues
por: Ibrahim, Omar M., et al.
Publicado: (2021)

USP1 Regulates TAZ Protein Stability Through Ubiquitin Modifications in Breast Cancer
por: Mussell, Ashley, et al.
Publicado: (2020)

Tumor growth fueled by spurious senescence phenotypes
por: Mastri, Michalis, et al.
Publicado: (2019)

Study on Attenuating Angiogenesis and Epithelial–Mesenchymal Transition (EMT) of Non-Small Cell Lung Carcinoma (NSCLC) by Regulating MAGEC2
por: Jiang, Sicong, et al.
Publicado: (2018)

Prostate cancer as a dedifferentiated organ: androgen receptor, cancer stem cells, and cancer stemness
por: Liu, Xiaozhuo, et al.
Publicado: (2022)

NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene
por: Mattila, Henna, et al.
Publicado: (2011)

Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers
por: Soni, Amy, et al.
Publicado: (2015)

First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients
por: Berinstein, Neil L, et al.
Publicado: (2012)

A randomized phase II study of pazopanib in hormone sensitive prostate cancer: a University of Chicago Phase II Consortium/ Department of Defense Prostate Cancer Clinical Trials Consortium study
por: Ward, James E., et al.
Publicado: (2011)

Connecting Prognostic Ligand Receptor Signaling Loops in Advanced Ovarian Cancer
por: Eng, Kevin H., et al.
Publicado: (2014)

Hemostatic matrix effects on blood loss after total knee arthroplasty: A randomized controlled trial
por: Di Francesco, Alexander, et al.
Publicado: (2013)

Differential Antigen Expression Profile Predicts Immunoreactive Subset of Advanced Ovarian Cancers
por: Eng, Kevin H., et al.
Publicado: (2014)

Immuno-stimultory/regulatory gene expression patterns in advanced ovarian cancer
por: Eng, Kevin H., et al.
Publicado: (2015)

Human Leukocyte Antigen (HLA) Influence on Prognosis of Autoimmune Hearing Loss
por: Psillas, George, et al.
Publicado: (2021)

Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553)
por: Arnold, Susanne M., et al.
Publicado: (2017)

Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study
por: Eng, Kevin H., et al.
Publicado: (2018)

The recent advancements of ferroptosis in the diagnosis, treatment and prognosis of ovarian cancer
por: Chen, Biqing, et al.
Publicado: (2023)

Are Early Relapses in Advanced-Stage Ovarian Cancer Doomed to a Poor Prognosis?
por: Vidal, Fabien, et al.
Publicado: (2016)

Tumor-infiltrating T lymphocyte clonality predicts prognosis in human ovarian cancer
por: Tsuji, Takemasa, et al.
Publicado: (2013)

Profound sensorineural hearing loss after one cycle of intraperitoneal cisplatin in treatment of advanced ovarian cancer
por: McDonald, Megan E., et al.
Publicado: (2017)

Effect of Muscle Loss but Not Fat Loss during Primary Debulking Surgery and Chemotherapy on Prognosis of Patients with Ovarian Cancer
por: Nakayama, Naomi, et al.
Publicado: (2022)

Impact of Underweight after Treatment on Prognosis of Advanced-Stage Ovarian Cancer
por: Kim, Se Ik, et al.
Publicado: (2014)

Recent advances of non-coding RNAs in ovarian cancer prognosis and therapeutics
por: Chen, Mengyu, et al.
Publicado: (2022)

Therapeutic Targeting of Collective Invasion in Ovarian Cancer
por: Moffitt, Laura, et al.
Publicado: (2019)

Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer
por: Ramakrishnan, Swathi, et al.
Publicado: (2019)

Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors
por: Vaghi, Cristina, et al.
Publicado: (2020)

T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors
por: Yamauchi, Takayoshi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pbvk8n3s5c8icjmqunhjthg5r7